AmpliTech Group, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AmpliTech Group, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.20M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $9.51M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $15.58M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $19.39M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $5.28M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.46M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $3.12M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.40M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $1.38M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $2.04M | Apr 2, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.20M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $9.51M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $15.58M | Mar 31, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.03M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.49M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $7.28M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $8.92M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.29M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.25M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.57M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.38M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $728.3K | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $1.21M | Apr 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.01M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($11.24M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($2.47M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($677.1K) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($4.76M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($1.03M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $5.9K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $329.0K | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($97.0K) | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $456.3K | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.32M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($8.43M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($2.58M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $151.0K | Apr 1, 2024 |
| FY2021 | Dec 31, 2021 | ($5.11M) | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | ($915.9K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $82.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $341.4K | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($90.1K) | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $471.9K | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.69M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.59M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.34M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.02M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.83M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $62.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $56.5K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $42.9K | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $68.4K | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $35.4K | Apr 2, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.66M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $7.86M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $7.51M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $7.63M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $4.56M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.11M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.48M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.04M | Mar 25, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.68M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($5.30M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($3.47M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($3.43M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($2.20M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($521.5K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($20.0K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $352.3K | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($166.8K) | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $346.7K | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.02M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $42.9K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $973.3K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $735.8K | Apr 1, 2024 |
| FY2021 | Dec 31, 2021 | $1.06M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $71.6K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $12.7K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($10.6K) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $5.4K | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $14.3K | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.48M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $43.22M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $31.41M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $36.68M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $35.23M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.81M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $3.36M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.41M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $665.5K | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $782.6K | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.62M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $5.73M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $4.73M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $7.92M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $6.19M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.37M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.27M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $492.5K | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $165.2K | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $185.2K | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.86M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $37.49M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $26.68M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $28.76M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $29.03M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $440.3K | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $1.09M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $915.3K | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $500.4K | Mar 25, 2020 |
| FY2018 | Dec 31, 2016 | $597.4K | Mar 21, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.70M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.70M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $4.70M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.70M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $4.82M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $120.1K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $120.1K | Mar 31, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($28.02M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($21.01M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($9.77M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($7.30M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($6.63M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($1.87M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($842.8K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($848.8K) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($1.18M) | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | ($1.08M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.98M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $19.32M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $6.73M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $13.29M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $18.02M | Mar 31, 2023 |
| FY2021 | Sep 30, 2021 | $22.95M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $199.5K | Mar 31, 2022 |
| FY2021 | Sep 30, 2020 | $425.9K | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | $574.7K | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $442.1K | Mar 31, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $80.8K | Apr 1, 2024 |
| FY2022 | Dec 31, 2022 | $234.0K | Mar 31, 2023 |
| FY2021 | Sep 30, 2021 | $330.4K | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | $1.60M | Mar 31, 2021 |
| FY2019 | Dec 31, 2019 | $1.49M | Mar 25, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 25, 2020 |
| FY2017 | Dec 31, 2017 | 0 | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Apr 2, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 25, 2020 |
| FY2017 | Dec 31, 2017 | 0 | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Apr 2, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 20.68M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 19.66M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 9.71M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 9.63M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 9.58M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 4.84M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 2.45M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 48.34M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | 46.14M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | 46.14M | Apr 2, 2018 |